PMID- 31443119
OWN - NLM
STAT- MEDLINE
DCOM- 20200113
LR  - 20200113
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 60
IP  - 5
DP  - 2019 Nov
TI  - Safety of intravenous immune globulin in an outpatient setting for patients with 
      neuromuscular disease.
PG  - 528-537
LID - 10.1002/mus.26678 [doi]
AB  - INTRODUCTION: Although intravenous immune globulin (IVIg) is used to treat 
      patients in the outpatient setting, there is limited documentation addressing the 
      safety of this practice. METHODS: Retrospective analysis of 438 patients with 
      neuromuscular diseases receiving IVIg in an outpatient setting. RESULTS: Adverse 
      events (AE) overall occurred in 16.9% of patients. Headache was the most common 
      AE, noted in 11.6% of patients. Serious AEs occurred in 0.91% of patients; 
      aseptic meningitis was the only one noted. Multivariate analyses identified the 
      following risk factors for AEs: first-lifetime course of IVIg, higher dose per 
      course of IVIg, diagnosis of myasthenia gravis, women, and younger age. 
      DISCUSSION: Intravenous immune globulin is generally safe to administer in an 
      outpatient setting. Women, myasthenia gravis patients, and those receiving their 
      first course or a higher total dose of IVIg are at an increased risk of 
      experiencing an AE.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Waheed, Waqar
AU  - Waheed W
AD  - Department of Neurological Sciences, University of Vermont, Robert Larner MD 
      College of Medicine, Burlington, Vermont.
AD  - Department of Neurological Sciences, University of Vermont Medical Center, 
      Burlington, Vermont.
FAU - Ayer, Gretchen A
AU  - Ayer GA
AD  - Option Care Enterprises, Bannockburn, Illinois.
FAU - Jadoo, Cindy L
AU  - Jadoo CL
AD  - South Shore Neurologic Associates, Islip, New York.
FAU - Badger, Gary J
AU  - Badger GJ
AD  - Department of Medical Biostatistics, University of Vermont, Burlington, Vermont.
FAU - Aboukhatwa, Marwa
AU  - Aboukhatwa M
AD  - Pharmacotherapy Service, University of Vermont Medical Center, Burlington, 
      Vermont.
AD  - Pharmacology Department, Medical Division, National Research Center, Cairo, 
      Egypt.
FAU - Brannagan, Thomas H 3rd
AU  - Brannagan TH 3rd
AD  - Department of Neurology, Columbia University, New York, New York.
FAU - Tandan, Rup
AU  - Tandan R
AD  - Department of Neurological Sciences, University of Vermont, Robert Larner MD 
      College of Medicine, Burlington, Vermont.
AD  - Department of Neurological Sciences, University of Vermont Medical Center, 
      Burlington, Vermont.
LA  - eng
PT  - Journal Article
DEP - 20190906
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Ambulatory Care
MH  - Exanthema/chemically induced
MH  - Female
MH  - Headache/chemically induced
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Infusions, Intravenous
MH  - Male
MH  - Meningitis, Aseptic/chemically induced
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myasthenia Gravis/therapy
MH  - Myositis/therapy
MH  - Neuromuscular Diseases/*therapy
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/therapy
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sex Factors
OTO - NOTNLM
OT  - adverse event
OT  - complications
OT  - intravenous immune globulin
OT  - myasthenia gravis
OT  - neuromuscular disease
OT  - outpatient infusion
EDAT- 2019/08/24 06:00
MHDA- 2020/01/14 06:00
CRDT- 2019/08/24 06:00
PHST- 2018/12/17 00:00 [received]
PHST- 2019/08/16 00:00 [revised]
PHST- 2019/08/20 00:00 [accepted]
PHST- 2019/08/24 06:00 [pubmed]
PHST- 2020/01/14 06:00 [medline]
PHST- 2019/08/24 06:00 [entrez]
AID - 10.1002/mus.26678 [doi]
PST - ppublish
SO  - Muscle Nerve. 2019 Nov;60(5):528-537. doi: 10.1002/mus.26678. Epub 2019 Sep 6.